CollPlant Biotechnologies (CLGN) FCF Margin (2018 - 2025)
CollPlant Biotechnologies (CLGN) posted FCF Margin of 4866.67% for Q4 2025, down 30.3% on a QoQ basis from 3735.06% in Q3 2025, and down 279045.0% year-over-year from N/an in Q4 2024.
CollPlant Biotechnologies (CLGN) FCF Margin (2018 - 2025) Analysis & Trends
CollPlant Biotechnologies' FCF Margin history runs 8 years deep, the most recent figure standing at 4866.67% for Q4 2025.
- Quarterly FCF Margin fell 279045.0% year-over-year to 4866.67% in Q4 2025, while the trailing twelve-month figure through Mar 2026 was 2116.45% (down 169416.0% YoY) and the FY2025 annual result came in at 396.08%, up 224664.0% from the prior year.
- FCF Margin was 4866.67% for Q4 2025 at CollPlant Biotechnologies, down from 3735.06% in the prior quarter.
- Across five years, FCF Margin topped out at 77.52% in Q1 2021 and bottomed at 82700.0% in Q3 2024.
- A 5-year average of 7373.63% and a median of 1538.19% in 2021 frame the typical range for FCF Margin.
- Annual changes were most pronounced in 2024 — FCF Margin sank 8270002 bps — and 2025, when it jumped 7896494 bps.
- CollPlant Biotechnologies' FCF Margin stood at 320.0% in 2021, then plunged by 6594 bps to 21420.69% in 2022, then jumped by 97 bps to 707.69% in 2023, then slumped by 193 bps to 2076.22% in 2024, then sank by 134 bps to 4866.67% in 2025.
- Business Quant data shows CLGN's FCF Margin at 4866.67% in Q4 2025, 3735.06% in Q3 2025, and 1361.45% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,831.58 Bn | 66,831.30 Bn | - | - |
| 2 | Nanobiotix | 1,916.61 Bn | 1,916.55 Bn | - | - |
| 3 | Akari Therapeutics | 976.78 Bn | 976.78 Bn | - | - |
| 4 | BeOne Medicines | 471.48 Bn | 466.69 Bn | 1.35 Bn | 10.45% |
| 5 | Vertex Pharmaceuticals | 121.78 Bn | 114.53 Bn | 2.59 Bn | 43.35% |
| 6 | Regeneron Pharmaceuticals | 69.87 Bn | 61.12 Bn | 3.31 Bn | 23.53% |
| 7 | Belite Bio | 63.06 Bn | 63.06 Bn | - | - |
| 8 | Argenx Se | 55.78 Bn | 50.60 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.54 Bn | 34.53 Bn | 959.66 Mn | 4.17% |
| 10 | CollPlant Biotechnologies | 4.63 Mn | 4.63 Mn | -243,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -4,866.67% |
| Sep 30, 2025 | -3,735.06% |
| Jun 30, 2025 | -1,361.45% |
| Dec 31, 2024 | -2,076.22% |
| Sep 30, 2024 | -82,700.00% |
| Jun 30, 2024 | -1,496.39% |
| Mar 31, 2024 | -3,235.71% |
| Dec 31, 2023 | -707.69% |
| Sep 30, 2023 | 0.02% |
| Jun 30, 2023 | -33.45% |
| Mar 31, 2023 | -763.28% |
| Dec 31, 2022 | -21,420.69% |
| Sep 30, 2022 | -2,638.53% |
| Jun 30, 2022 | -5,413.64% |
| Dec 31, 2021 | -320.00% |
| Sep 30, 2021 | -1,580.00% |
| Jun 30, 2021 | -454.12% |
| Mar 31, 2021 | 77.52% |
| Dec 31, 2020 | -65.47% |
| Sep 30, 2020 | 37,970.11% |